×

Biotech and Pharmaceuticals Medicine

  • BEIJING, July 12- China's program to vaccinate poultry against the H7N9 strain of bird flu will be carried out nationwide from this autumn, the country's agriculture ministry said on Monday. Beijing will also strengthen inspections and supervision on poultry being transported between provinces, the ministry said in a document. Farmers in China have been...

  • July 11- CVS Health Corp has paid $5 million to resolve allegations that pharmacies it operates in California failed to keep and maintain accurate records of prescription drugs, the U.S. Justice Department said on Tuesday. Opioids, including prescription painkillers and heroin, killed more than 33,000 people in the United States in 2015, more than any year on...

  • The deal, in which Mallinckrodt did not admit wrongdoing, marked a record settlement of claims that a drugmaker failed to properly notify the U.S. Drug Enforcement Administration of suspicious orders for drugs such as oxycodone, the Justice Department said. Attorney General Jeff Sessions said the settlement will send a message to other drugmakers that the...

  • Coffee drinking could lead to longer life, studies say

    Drinking coffee could reduce chances of dying from a host of diseases, including heart disease and stroke, according to two studies.

  • CHICAGO, July 11- American technology. In Texas, Microsoft is testing a smart trap to isolate and capture Aedes aegypti mosquitoes, known Zika carriers, for study by entomologists to give them a jump on predicting outbreaks. The Zika epidemic that emerged in Brazil in 2015 and left thousands of babies suffering from birth defects has added urgency to the effort.

  • *Share of big $11 bln hemophilia market at stake. ZURICH, July 10- Swiss drugmaker Roche's bid to take a chunk of the $11 billion hemophilia drug market dominated by Shire took another blow with the Irish company winning a preliminary injunction over its Swiss rival's medication. Shire said its injunction in a court in Germany, where Roche presented data on its...

  • *Share of big $11 bln hemophilia market at stake. ZURICH, July 10- Swiss drugmaker Roche's bid to take a chunk of the $11 billion hemophilia drug market dominated by Shire took another blow with the Irish company winning a preliminary injunction over its Swiss rival's medication. Shire said its injunction in a court in Germany, where Roche presented data on its...

  • July 10- Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss. The FDA had imposed a hold on the mid-stage study in May and asked for more data before Concert could proceed with dosing patients. The disease affects about 4.6 million people in the...

  • The ability to pay for health-care needs is one of the most critical issues of retirement.

    Experts say now is a good time for older Americans to review their options, especially if Medicaid is cut.

  • July 10- Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted the clinical hold on a mid-stage study testing its drug to treat alopecia areata, a type of hair loss.

  • ZURICH, July 10- Roche's bid to muscle in on Shire's share of the $11 billion hemophilia drug market took a new, contentious turn this weekend when the British drugmaker won a court injunction against how the Swiss drugmaker talks about its new medicine. Shire's injunction on Sunday in a Hamburg, Germany, court alleges incomplete and misleading statements by...

  • Other companies developing treatments for glaucoma include Aerie Pharmaceuticals Inc, which is awaiting the U.S. Food and Drug Administration's decision on its drug Rhopressa and a device by Ocular Therapeutix Inc that can be inserted into the eye to deliver regular glaucoma medication. Glaucoma is considered the second-leading cause of blindness in the...

  • July 7- Inotek Pharmaceuticals Corp said on Friday it would evaluate strategic options after its sole experimental eye drug failed another trial, sending the company's shares tumbling 42 percent in extended trading. Glaucoma is considered the second-leading cause of blindness in the world, according to the World Health Organization.

  • Dr. Kenneth Davis

    It's very difficult to see how a lot of urban hospitals are going to survive under GOP health-care legislation, Dr. Kenneth Davis said.

  • July 6- Celgene Corp said it would buy a stake in BeiGene Ltd to help develop and commercialize the China- based cancer immunotherapy developer's treatment for solid tumor cancers, expanding its position in the field of immuno-oncology. The deal announced on Wednesday will complement Celgene's partnership with AstraZeneca Plc to develop durvalumab as a...

  • Celgene will acquire 32.7 million, or 5.9 percent of BeiGene's ordinary shares, at $4.58 each, or $59.55 per BeiGene's American Depositary Shares, they said in a statement. BeiGene will receive $263 million in upfront license fees and $150 million equity investment. BeiGene will acquire Celgene's operations in China and will also license and assume...

  • July 5- Merck& Co Inc said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its immunotherapy drug, Keytruda, in combination with other therapies. The health regulator said the risks of the combination studies, Keynote-183, Keynote-185 and Keynote-023, outweigh any potential benefit for...

  • *New-style vaccines from German, U.S. teams cut relapses. *Roche already in $310 mln deal with Germany's BioNTech. LONDON, July 5- A novel class of personalised cancer vaccines, tailored to the tumours of individual patients, kept disease in check in two early-stage clinical trials, pointing to a new way to help the immune system fight back.

  • LONDON, July 5- The threat of slowing demand and new competition in GlaxoSmithKline's flagship HIV drug business unnerved investors in Britain's biggest drugmaker on Wednesday, sending its shares down as much as 1.8 percent. GSK pared losses to 0.8 percent by 1220 GMT but remained among the top losers in London's FTSE-100 index after Citigroup downgraded the...

  • Pharmacy benefits manager Appro-Rx on bringing clarity to drug prices

    Kyle Fields, Appro-Rx CEO, discusses how his company is working on transparency in drug pricing as a pharmacy benefits manager.